Literature DB >> 24133591

MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1β induced in human endometriosis stromal cells in vitro.

Fengying Huang1, Jing Cao, Qiuhong Liu, Ying Zou, Hongyun Li, Tuanfang Yin.   

Abstract

OBJECTIVE: Now there are more and more evidences that Cyclooxygenase-2 (COX-2) plays an important role in angiogenesis of endometriosis (EMs). Vascular endothelial growth factor (VEGF) has a potent angiogenic activity. However, it is worth studying about the regulating mechanism of COX-2/COX-1 and VEGF in the development of human endometriosis in vitro. The current study was designed to investigate the effect of 4 cytokines on COX-2/COX-1 expression and the effect of IL-1β on VEGF release in human endometriosis stromal cells (ESC), and to explore the related signaling pathways involved in vitro.
METHODS: Isolation, culture and identification of ESC. Cells were treated with 4 cytokines, and the inhibitor mitogen-activated protein-Erk (MEK) and the inhibitor p38 mitogen-activated protein kinase (MAPK) prior to adding cytokine IL-1β. COX-2 protein expression was measured by western blot and VEGF secretion was determined by ELISA.
RESULTS: Among four kinds of cytokines, IL-1β treatment increased COX-2 protein expression and VEGF release in three ESC, and TNF-α had the same effect on COX-2 protein level as IL-1β only in ectopic and eutopic ESC, and MCSF had only slight effect on ectopic ESC. In contrast, cytokines had no effect on COX-1 expression. We also demonstrated that MAPK reduced the synthesis of COX-2 by IL-1β induced. COX-2 inhibitor reduced VEGF release by IL-1β induced.
CONCLUSIONS: i) In human ESC in vitro, IL-1β up-regulated the COX-2 expression through the activation of p38 MAPK pathway, and not to COX-1. ii) Up-regulation of VEGF level by IL-1β treatment was found in human endometriosis stromal cell and COX-2 inhibitor was involved in this process.

Entities:  

Keywords:  Endometriosis stromal cells (ESC); cyclooxygenase-2 (COX-2); cytokines; in vitro; signal pathways; vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2013        PMID: 24133591      PMCID: PMC3796235     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis.

Authors:  Meng-Hsing Wu; H Sunny Sun; Chen-Chung Lin; Kuei-Yang Hsiao; Pei-Chin Chuang; Hsien-An Pan; Shaw-Jenq Tsai
Journal:  Mol Hum Reprod       Date:  2002-12       Impact factor: 4.025

Review 2.  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration.

Authors:  Shahin Rafii; David Lyden
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

3.  PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells.

Authors:  Guido Eibl; Dennis Bruemmer; Yuji Okada; John P Duffy; Ronald E Law; Howard A Reber; Oscar J Hines
Journal:  Biochem Biophys Res Commun       Date:  2003-07-11       Impact factor: 3.575

4.  cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.

Authors:  M K O'Banion; V D Winn; D A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

5.  Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.

Authors:  Yoshihira Kimba; Tatsuya Abe; Jian Liang Wu; Ryo Inoue; Minoru Fukiki; Kimitoshi Kohno; Hidenori Kobayashi
Journal:  Oncol Res       Date:  2005       Impact factor: 5.574

6.  Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis.

Authors:  J McLaren; A Prentice; D S Charnock-Jones; S K Smith
Journal:  Hum Reprod       Date:  1996-01       Impact factor: 6.918

7.  Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis.

Authors:  M L Hull; A Prentice; D Y Wang; R P Butt; S C Phillips; S K Smith; D S Charnock-Jones
Journal:  Hum Reprod       Date:  2004-11-26       Impact factor: 6.918

8.  COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.

Authors:  Satoko Yoshida; Hideki Amano; Izumi Hayashi; Hidero Kitasato; Mariko Kamata; Madoka Inukai; Hirokuni Yoshimura; Masataka Majima
Journal:  Lab Invest       Date:  2003-10       Impact factor: 5.662

9.  Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.

Authors:  Young-Eun Joo; Jong-Sun Rew; Young-Ho Seo; Sung-Kyu Choi; Young-Jin Kim; Chang-Soo Park; Sei-Jong Kim
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

10.  Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

Authors:  Min Yao; Stacia Kargman; Eugene C Lam; Colleen R Kelly; Yaxin Zheng; Pauline Luk; Elizabeth Kwong; Jilly F Evans; M Michael Wolfe
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

View more
  13 in total

Review 1.  Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer.

Authors:  Shreena J Desai; Ben Prickril; Avraham Rasooly
Journal:  Nutr Cancer       Date:  2018-03-26       Impact factor: 2.900

2.  IL-1β Inhibits Connexin 43 and Disrupts Decidualization of Human Endometrial Stromal Cells Through ERK1/2 and p38 MAP Kinase.

Authors:  Jie Yu; Sarah L Berga; Wei Zou; D Grace Yook; Joshua C Pan; Aurora Arroyo Andrade; Lijuan Zhao; Neil Sidell; Indrani C Bagchi; Milan K Bagchi; Robert N Taylor
Journal:  Endocrinology       Date:  2017-12-01       Impact factor: 4.736

3.  Neurons and astroglia govern microglial endotoxin tolerance through macrophage colony-stimulating factor receptor-mediated ERK1/2 signals.

Authors:  Chun-Hsien Chu; Shijun Wang; Chia-Ling Li; Shih-Heng Chen; Chih-Fen Hu; Yi-Lun Chung; Shiou-Lan Chen; Qingshan Wang; Ru-Band Lu; Hui-Ming Gao; Jau-Shyong Hong
Journal:  Brain Behav Immun       Date:  2016-04-27       Impact factor: 7.217

4.  Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population.

Authors:  Xiao-Nv Xie; Jing Yu; Li-Hua Zhang; Zhi-Ying Luo; Dong-Sheng Ouyang; Ling-Jie Zheng; Chun-Yang Wang; Li Yang; Ling Chen; Zhi-Rong Tan
Journal:  Funct Integr Genomics       Date:  2018-10-20       Impact factor: 3.410

5.  Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.

Authors:  Joel D Maust; Christy L Frankowski-McGregor; Armand Bankhead; Diane M Simeone; Judith S Sebolt-Leopold
Journal:  Mol Cancer Ther       Date:  2018-09-25       Impact factor: 6.261

6.  Triterpenoid saponin flaccidoside II from Anemone flaccida triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors via the MAPK-HO-1 pathway.

Authors:  Lin-Tao Han; Yin Fang; Yan Cao; Feng-Hua Wu; E Liu; Guo-Yan Mo; Fang Huang
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147

7.  Suppression of Human Tenon Fibroblast Cell Proliferation by Lentivirus-Mediated VEGF Small Hairpin RNA.

Authors:  Zhongqiu Li; Wen Hua; Xuedong Li; Wei Wang
Journal:  J Ophthalmol       Date:  2017-01-11       Impact factor: 1.909

Review 8.  A novel and compact review on the role of oxidative stress in female reproduction.

Authors:  Jiayin Lu; Zixu Wang; Jing Cao; Yaoxing Chen; Yulan Dong
Journal:  Reprod Biol Endocrinol       Date:  2018-08-20       Impact factor: 5.211

9.  Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer.

Authors:  Nan-Nan Li; Xian-Sheng Meng; Yong-Rui Bao; Shuai Wang; Tian-Jiao Li
Journal:  Pharmacogn Mag       Date:  2018-04-10       Impact factor: 1.085

10.  Microglia enhanced the angiogenesis, migration and proliferation of co-cultured RMECs.

Authors:  Xinyi Ding; Ruiping Gu; Meng Zhang; Hui Ren; Qinmeng Shu; Gezhi Xu; Haixiang Wu
Journal:  BMC Ophthalmol       Date:  2018-09-17       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.